Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neurogen To Try Adipiplon In Crossover Study With Ambien

This article was originally published in The Pink Sheet Daily

Executive Summary

Anxiety, schizophrenia studies also part of broad effort to develop GABA-based insomnia agent.

You may also be interested in...



Neurogen Raises Cash, Cuts Staff

Lead candidate for insomnia targets “lifestyle” market, pharmacist tells “The Pink Sheet” DAILY.

Neurogen Raises Cash, Cuts Staff

Lead candidate for insomnia targets “lifestyle” market, pharmacist tells “The Pink Sheet” DAILY.

Neurogen Will Advance Insomnia Drug Based On Positive Top-Line Phase IIb Results

Improved specificity will make NG2-73 first-line therapy of choice for the vast majority of insomnia sufferers, Neurogen R&D chief says.

Topics

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel